Local drug delivery for the prevention of restenosis: Fact, fancy, and future

Circulation

Volumn 90, Issue 4 I, 1994, Pages 2070-2084

  Lincoff, A Michael ^a   Topol, Eric J ^a   Ellis, Stephen G ^a,b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b Ctr for Thromb and Vasc Biology ^*

Author keywords

angioplasty; Current Perspectives; restenosis; stents

Indexed keywords

POLYMER; PROGESTERONE;

ATHERECTOMY; ATHEROSCLEROSIS; BALLOON CATHETER; CLONING VECTOR; DRUG DELIVERY SYSTEM; HEART MUSCLE REVASCULARIZATION; HUMAN; MITRAL VALVE STENOSIS; PATIENT SELECTION; PHARMACEUTICS; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; STENT; STEROID THERAPY;

EID: 0028092125     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.90.4.2070     Document Type: Review

References (122)

1. Popma JJ, Califf RM, Topol EJ. Clinical trials of restenosis after coronary angioplasty. Circulation. 1991;84:1426-1436.
2. Topol EJ, Ellis SG, Cosgrove DM, Bates ER, Muller DWM, Schork NJ, Loop FD. Analysis of coronary angioplasty practice in the United States with an insurance-claims data base. Circulation. 1993;87:1489-1497.
3. Waller BF, Pinkerton CA, Orr CM, Slack JD, Van Tassel JW, Peters T. Restenosis 1 to 24 months after clinically successful coronary balloon angioplasty: a necropsy study of 20 patients. J Am Coll Cardiol. 1991;17:58B-70B.
4. Noboyoshi M, Kimura T, Ohishi H, Horiuchi H, Nosaka H, Hamasaki N, Yokoi H, Kim K. Restenosis after percutaneous transluminal coronary angioplasty: pathologic observations in 20 patients. J Am Coll Cardiol. 1991;17:433-439.
5. Kovach JA, Mintz GS, Pichard AD, Kent KM, Popma JJ, Satler LF, Leon MB. Sequential intravascular ultrasound characterization of the mechanisms of rotational atherectomy and adjunct balloon angioplasty. J Am Coll Cardiol. 1993;22:1024-1032.
6. Mintz GS, Douek PC, Bonner RF, Kent KM, Pichard AD, Satler LF, Leon MB. Intravascular ultrasound comparison of de novo and restenotic coronary lesions. J Am Coll Cardiol. 1993;21:118A. Abstract.
7. Ip JH, Fuster V, Badimon L, Badimon J, Taubman MB, Chesebro JH. Syndromes of accelerated atherosclerosis: role of vascular injury and smooth muscle cell proliferation. J Am Coll Cardiol. 1990;15:1667-1687.
8. Forrester JS, Fishbein M, Helfant R, Fagin J. A paradigm for restenosis based on cell biology: clues for the development of new preventive therapies. J Am Coll Cardiol. 1991;17:758-769.
9. Ellis SG, Savage M, Fischman D, Baim DS, Leon MS, Goldberg S, Hirshfeld JW, Cleman MW, Teirstein PS, Walker C, Bailey S, Buchbinder M, Topol EJ, Schatz RA. Restenosis after placement of Palmaz-Schatz stents in native coronary arteries: initial results of a multicenter experience. Circulation. 1992;86: 1836-1844.
10. de Jaegere PP, Serruys PW, Bertrand M, Wiegand V, Kober G, Marquis JF, Valeix B, Uebis R, Piessens J. Wiktor stent implantation in patients with restenosis following balloon angioplasty of a native coronary artery. Am J Cardiol. 1992;69:598-602.
11. Topol EJ, Leya F, Pinkerton CA, Whitlow PL, Hofling B, Simonton CA, Masden RR, Serruys PW, Leon MB, Williams DO, King SBI, Mark DB, Isner JM, Holmes DRJ, Ellis SG, Lee KL, Keeler G, Berdan LG, Hinohara T, Califf RM, on behalf of the CAVEAT Study Group. A comparison of coronary angioplasty with directional atherectomy in patients with coronary artery disease. N Engl J Med. 1993;329:221-227.
12. Garratt KN, Holmes DR, Bell MR, Berger PB, Kaufmann UP, Bresnahan JF, Vlietstra RE. Results of directional atherectomy of primary atheromatous and restenosis lesions in coronary arteries and saphenous vein grafts. Am J Cardiol. 1992;70: 449-454.
13. De Cesare NB, Popma JL, Holmes DRJ, Dick RJ, Whitlow PL, King SB, Pinkerton CA, Kereiakes DJ, Topol EJ, Haudenschild CC, Ellis SG. Clinical angiographic and histologic correlates of ectasia after directional coronary atherectomy. Am J Cardiol. 1992;69:314-319.
14. Teirstein PS, Warth DC, Haq N, Jenkins NS, McCowan LC, Aubanel-Reidel P, Morris N, Ginsburg R. High speed rotational coronary atherectomy for patients with diffuse coronary artery disease. J Am Coll Cardiol. 1991;18:1694-1701.
15. Bertrand M, Lablanche JM, Leroy F, Bauters C, De Jaegere P, Serruys PW, Meyer J, Dietz U, Erbel R. Percutaneous transluminal coronary rotary ablation with Rotablator (European experience). Am J Cardiol. 1992;69:470-474.
16. Spears JR, Reyes VP, Wynne J, Fromm BS, Sinofsky E, Andrus S, Sinclair IN, Hopkins BE, Schwartz L, Aldridge HE, Plokker HWT, Mast EG, Rickards A, Knudtson ML, Sigwart Uh, Dear WE, Ferguson JJ, Angelini P, Leatherman LL, Safian RD, Jenkins RD, Douglas JS, King SB. Percutaneous coronary laser balloon angioplasty: initial results of a multicenter experience. J Am Coll Cardiol. 1990;16:293-303.
17. Bittl JA, Sanborn TA, Tcheng JE, Siegel RM, Ellis SG. Clinical success, complications and restenosis rates with excimer laser coronary angioplasty. Am J Cardiol. 1992;70:1533-1539.
18. Schatz RA, Penn IM, Baim DS, Nobuyoshi M, Colombo A, Ricci DR, Clemen MW, Goldberg S, Heuser RR, Almond D, Fish D, Moses J, Gallup D, Detre K, Leon MB, for the STRESS Investigators. STent REStenosis Study (STRESS): analysis of in-hospital results. Circulation. 1993;88(suppl I):I-594. Abstract.
19. Serruys PW, Macaya C, de Jaegere P, Kiemeneij F, Rutsch W, Heyndrickx G, Emanuelsson H, Marco J, Legrand V, Materne P, Belardi J, Buller N, Colombo A, Goy JJ, Delcan J, Morel M, on behalf of the Benestent study group: interim analysis of the BENESTENT Trial. Circulation. 1993;88(suppl I):I-594. Abstract.
20. Hillegass WB, Ohman EM, Califf RM. Restenosis: the clinical issues. In: Topol EJ, ed. Textbook of Interventional Cardiology, 2nd ed. Philadelphia, Pa: WB Saunders Co; 1993:415-435.
21. Ferrell M, Fuster V, Gold HK, Chesebro JH. A dilemma for the 1990s: choosing appropriate experimental animal model for the prevention of restenosis. Circulation. 1992;85:1630-1631. Editorial comment.
22. Powell JS, Muller RKM, Baumgartner HR. Suppression of the vascular response to injury: the role of angiotensin-converting enzyme inhibitors. J Am Coll Cardiol. 1991;17:137B-142B.
23. Currier JW, Pow TK, Haudenschild CC, Minihan AC, Faxon DP. Low molecular weight heparin (Enoxaparin) reduces restenosis after iliac angioplasty in the hypercholesterolemic rabbit. J Am Coll Cardiol. 1991;17:118B-125B.
24. Multicenter European Research Trial with Cilazapril after Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MERCATOR) Study Group. Does the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty? Results of the MERCATOR study: a multicenter, randomized, double-blind placebo-controlled trial. Circulation. 1992;86:100-110.
25. Faxon D, Spiro T, Minor S, Douglas J, Cote G, Dorosti K, Gottlieb R, Califf R, Topol E, Gordon J. Enoxaparin, a low molecular weight heparin, in the prevention of restenosis after angioplasty: results of a double blind randomized trial. J Am Coll Cardiol. 1992;19:258A. Abstract.
26. Wallace BM, Lasker JS. Stand and deliver: getting peptide drugs into the body. Science. 1993;260:912-913.
27. Davis SS. Delivery systems for biopharmaceuticals. J Pharm Pharmacol. 1992;44(suppl 1):186-190.
28. Hoover JL, Rush BD, Wilkinson KF, Day JS, Burton PS, Vidmar TJ, Ruwart MJ. Peptides are better absorbed from the lung than the gut in the rat. Pharm Res. 1992;9:1103-1106.
29. Theiss U, Kuhn I, Lucker PW. Iontophoresis-is there a future for clinical application? Methods Find Exp Clin Pharmacol. 1991; 13:353-359.
30. Langer R. New methods of drug delivery. Science. 1990;249: 1527-1533.
31. Levy RJ, Wolfrum J, Schoen FJ, Hawley MA, Lund S, Langer R. Inhibition of calcification of bioprostentic heart valve calcification by local controlled release of diphosphonate. Science. 1985;228: 190-192.
32. Sintov A, Scott WA, Gallagher KP, Levy RJ. Conversion of ouabain-induced ventricular tachycardia in dogs with epicardial lidocaine: pharmacodynamics and functional effects. Pharm Res. 1990;7:28-33.
33. Radovsky AS, Van Vleet JF. Effects of dexamethasone elution on tissue reaction around stimulating electrodes of endocardial pacing leads in dogs. Am Heart J. 1989;117:1288.
34. Edelman ER, Adams DH, Karnovsky MJ. Effect of controlled adventitial heparin delivery on smooth muscle cell proliferation following endothelial injury. Proc Natl Acad Sci U S A. 1990;87: 3773-3777.
35. Simons M, Edelman ER, DeKeyser JL, Langer R, Rosenberg RD. Antisense c-myb oligonucleotides inhibit intimai arterial smooth muscle cell accumulation in vivo. Nature. 1992;359:67-70.
36. Villa AE, Guzman LA, Chen W, Golomb G, Levy RJ, Topol EJ. Local delivery of dexamethasone for prevention of neointimal proliferation in a rat model of balloon angioplasty. J Clin Invest. 1994;93:1243-1249.
37. Schwartz RS, Huber KC, Murphy JG, Edwards WD, Camrud AR, Vlietstra RE, Holmes DR. Restenosis and the proportional neointimal response to coronary artery injury: results in a porcine model, J Am Coll Cardiol 1992;19:267-274.
38. Kuntz RE, Gibson CM, Nobuyoshi M, Baim DS. Generalized model of restenosis after conventional balloon angioplasty, stenting, and directional atherectomy. J Am Coll Cardiol. 1993; 21:15-25.
39. Duncan LEJ, Cornfield J, Buck K. Effect of blood pressure on passage of labelled plasma albumin into canine aortic wall. J Clin Invest. 1962;41:1537-1545.
40. 131I-fibrinogen in the pig aorta in vivo. Exp Mol Pathol. 1974;20:281-292.
41. Wolinsky H, Thung SN. Use of a perforated balloon catheter to deliver concentrated heparin into the wall of the normal canine artery. J Am Coll Cardiol. 1990;15:475-481.
42. Wolinsky H, Lin CS. Use of the perforated balloon catheter to infuse marker substances into diseased coronary artery walls after experimental postmortem angioplasty. J Am Coll Cardiol. 1991; 17:174B-178B.
43. Goldman B, Blanke H, Wolinsky H. Influence of pressure on permeability of normal and diseased muscular arteries to horseradish peroxidase. Atherosclerosis. 1987;65:215-225.
44. Penn MS, Koelle MR, Schwartz SM, Chisolm GM. Visualization and quantification of transmural concentration profiles of macromolecules across the arterial wall. Circ Res. 1990;67:11-22.
45. Wilensky RL, March KL, Hathaway DR. Direct intraarterial wall injection of microparticles via a catheter: a potential drug delivery strategy following angioplasty. Am Heart J. 1991;122:1136-1140.
46. Wilensky RL, March KL, Gradus-Pizlo I, Spaedy AJ, Hathaway DR. Methods and devices for local drug delivery in coronary and peripheral arteries. Trends Cardiovasc Med. 1993;3:163-170.
47. Lambert CR, Leone JE, Rowland SM. Local drug delivery catheters: functional comparison of porous and microporous designs. Cor Art Dis. 1993:4:469-475.
48. Stadius ML, Collins C, Kernoff R. Local infusion balloon angioplasty to obviate restenosis compared with conventional balloon angioplasty in an experimental model of atherosclerosis. Am Heart J. 1993;126:47-56.
49. Hong MK, Wong SC, Farb A, Mehlman MD, Virmani R, Barry JJ, Leon MB. Feasibility and drug delivery efficiency of a new balloon angioplasty catheter capable of performing simultaneous local drug delivery. Cor Art Dis. 1993;4:1023-1027.
50. Cumberland DC, Gunn J, Tsikaderis D, Arafa S, Ahsan A. Initial clinical experience of local drug delivery via a porous balloon during percutaneous coronary angioplasty. J Am Coll Cardiol. 1994;23:186A. Abstract.
51. Azrin MA, Mitchel JF, Bow LM, Alberghini TV, Peck R, Fram DB, Waters D, McKay RG. Effect of local delivery of heparin on platelet deposition during in vivo balloon angioplasty using hydrogel-coated balloons. Circulation. 1993;88(suppl I):I-310. Abstract.
52. Kaplan AV, Kermode J, Grant G, Klein E, Vetter J, Hinohara T, Simpson JB. Intramural delivery of marker agent in ex vivo and in vivo models using a novel drug delivery sleeve. J Am Coll Cardiol. 1994;23:187A. Abstract.
53. Lincoff AM, Furst JG, Penn MS, Lee P, MacIsaac AI, Chisolm GM, Topol EJ. Efficiency of solute transfer by a microporous balloon balloon catheter in the porcine coronary model of arterial injury. J Am Coll Cardiol. 1994;23:18A. Abstract.
54. Barger AC, Beeuwkes R, Lainey LL, Silverman KJ. Hypothesis: vasa vasorum and neovascularization of human coronary arteries. N Engl J Med. 1984;310:175-177.
55. Muller DWM, Topol EJ, Abrams GD, Ellis SG. Intramural methotrexate therapy for prevention of neointimal thickening after balloon angioplasty. J Am Coll Cardiol. 1992;20:460-466.
56. 3 catheter. J Am Coll Cardiol. 1994;23:186A. Abstract.
57. Carrozza JP, Kuntz RE, Levine MJ, Pomerantz RM, Fishman RF, Mansour M, Gibson CM, Senerchia CC, Diver DJ, Safian RD, Baim DS. Angiographic and clinical outcome of intracoronary stenting: immediate and long-term results from a large single-center experience. J Am Coll Cardiol. 1992;20:328-337.
58. Kimura T, Nosaka H, Yokoi H, Iwabuchi M, Nobuyoshi M. Serial angiographic follow-up after Palmaz-Schatz stent implantation: comparison with conventional balloon angioplasty. J Am Coll Cardiol. 1993;21:1557-1563.
59. Muller DWM, Ellis SG. Advances in coronary angioplasty: endovascular stents. Cor Art Dis. 1990;1:438-448.
60. Murphy JG, Schwartz RS, Edwards WD, Camrud AR, Vlietstra RE, Holmes DR. Percutaneous polymeric stents in porcine coronary arteries: initial experience with polyethylene terephthalate stents. Circulation. 1992;86:1596-1604.
61. Lincoff AM, van der Giessen WJ, Schwartz RS, van Beusekom HMM, Serruys PW, Holmes DR, Ellis SG, Topol EJ. Biodegradable and biostable polymers may both cause vigorous inflammatory responses when implanted in the porcine coronary artery. J Am Coll Cardiol. 1993;21:179A. Abstract.
62. Zidar JP, Lincoff AM, Stack RS. Biodegradable stents. In: Topol EJ, ed. Textbook of Interventional Cardiology, 2nd ed. Philadelphia, Pa: WB Saunders Co; 1993:787-802.
63. Lincoff AM, Furst JG, Ellis SG, Topol EJ. Sustained local drug delivery by a novel intravascular eluting stent to prevent restenosis in the porcine coronary artery. J Am Coll Cardiol. 1994;23:18A. Abstract.
64. Holmes DR, Edwards WD, Camrud AR, Jorgenson MA, Schwartz RS. Differential arterial response to stents in a porcine coronary model: exogenous fibrin vs polyurethane vs polyethylene terephthalate. J Am Coll Cardiol. 1993;21:179A. Abstract.
65. Fernandez-Ortiz A, Meyer BJ, Mailhac A, Chesebro JH, Badimon L, Hassinger N, Owen WG, Fuster V, Badimon JJ. Intravascular local delivery: an iontophoretic approach. Circulation. 1993;88(suppl I):I-308. Abstract.
66. Dev V, Zeng H, Forrester J, Eigler N, Hickey AJ, Fishbein MC, Litvack F. Biodegradable microspheres for sustained drug delivery to the arterial wall. Circulation. 1993;88(suppl I):I-311. Abstract.
67. Farb A, Carlson GC, Virmani R. In vivo local delivery and persistence of small and large particles following balloon angioplasty of atherosclerotic arteries: histologic confirmation. Circulation. 1993;88(suppl I):I-310. Abstract.
68. Dev V, Zeng H, Forrester JS, Eigler N, Tian Y, Hickey AJ, Fishbein MC, Kupfer J, Litvack F. Microspheres for drug delivery to the arterial wall: a study of kinetics, toxicity, and effects of coroticosteroid loaded microspheres. J Am Coll Cardiol. 1994; 23:19A. Abstract.
69. Robinson KA, Waksman R, Thomas C, Sigman SR, Cipolla GD, Britt B, Santoian EC, Tarazona N, King SB. The porous balloon catheter deposits gold microparticle suspension primarily at the site of medial fracture in balloon dilated pig coronary arteries. J Am Coll Cardiol. 1994;23:188A. Abstract.
70. Dichek DA, Neville RF, Zwiebel JA, Freeman SM, Leon MB, Anderson WF. Seeding of intravascular stents with genetically engineered endothelial cells, Circulation. 1989;80:1347-1353.
71. Plautz G, Nabel E, Nabel GJ. Introduction of vascular smooth muscle cells expressing recombinant genes in vivo. Circulation. 1991;83:578-583.
72. Chapman G, Lim C, Gammon R, Culp S, Desper J, Bauman R, Swain J, Stack R. Gene transfer into coronary arteries of intact animals with a percutaneous balloon catheter. Circ Res. 1992;71: 27-33.
73. Nabel EG, Plautz G, Nabel GJ. Site-specific gene expression in vivo by direct gene transfer into the arterial wall. Science. 1990; 249:1285-1288.
74. Morishita R, Gibbons GH, Kaneda Y, Ogihara T, Dzau VJ. Novel in vitro gene transfer method for study of local modulators in vascular smooth muscle cells. Hypertension. 1993;21:894-899.
75. Kahn ML, Lee SW, Dichek D. Optimization of retroviral vector-mediated gene transfer into endothelial cells in vitro. Circ Res. 1992;71:1508-1517.
76. Lemarchand P, Jones M, Yamada I, Crystal RG. In vivo gene transfer and expression in normal uninjured blood vessels using replication-deficient recombinant adenovirus vectors. Circ Res. 1993;72:1132-1138.
77. Lee SW, Trapnell BC, Rade JJ, Virmani R, Dichek DA. In vivo adenoviral vector-mediated gene transfer into balloon-injured rat carotid arteries. Circ Res. 1993;73:797-807.
78. Leclerc G, Gal D, Takeshita S, Nikol S, Weir L, Isner J. Percutaneous arterial gene transfer in a rabbit model: efficiency in normal and balloon-dilated atherosclerotic arteries. J Clin Invest. 1992;90:936-944.
79. Flugelman MY, Jaklitsch MT, Newman KD, Casscells W, Bratthauer GL, Dichek DA. Low level in vivo gene transfer into the arterial wall through a perforated balloon catheter. Circulation. 1992;85:1110-1117.
80. Willard JE, Jessen ME, Gerard RD, Meidell RS. Recombinant adenovirus is an efficient vector for in vivo gene transfer and can be preferentially directed at vascular endothelium or smooth muscle cells. Circulation. 1992;86(suppl I):I-473. Abstract.
81. Casscells W, Lappi DA, Olwin BB, Wai C, Siegman M, Speir EH, Sasse J, Baird A. Elimination of smooth muscle cells in experimental restenosis: targeting of fibroblast growth factor receptors. Proc Natl Acad Sci U S A. 1992;89:7159-7163.
82. Epstein SE, Siegall CB, Biro S, Fu YM, FitzGerald D, Pastan I. Cytotoxic effects of a recombinant chimeric toxin on rapidly proliferating vascular smooth muscle cells. Circulation. 1991;84: 778-787.
83. Pickering JG, Bacha PA, Weir L, Jekanowski J, Nichols JC, Isner JM. Prevention of smooth muscle cell outgrowth from human atherosclerotic plaque by a recombinant cytoxin specific for the epidermal growth factor receptor. J Clin Invest. 1993;91:724-729.
84. Muller DWM, Ellis SG, Topol EJ. Experimental models of coronary artery restenosis. J Am Coll Cardiol. 1992;19:418-432.
85. Clowes AW, Reidy MA, Clowes MM. Kinetics of cellular proliferation after arterial injury. I. Smooth muscle growth in the absence of endothelium. Lab Invest. 1983;49:327-333.
86. Clowes AW, Reidy MA, Clowes MM. Mechanisms of stenosis after arterial injury. Lab Invest. 1983;49:208-215.
87. Rozengurt E. Early signals in the mitogenic response. Science. 1986;234:161-166.
88. Schwartz SM, Majesky MW, Reidy M. Molecular signals controlling smooth muscle cell proliferation in hypertension and atherosclerosis. In: Roberts R, ed. Molecular Basis of Cardiology. Cambridge, Mass: Blackwell Scientific Publications; 1993: 135-170.
89. Hunter T, Karin M. The regulation of transcription by phosphorylation. Cell. 1992;70:375-387.
90. Holt JT, Gopal TV, Moulton AD, Nienhuis AW. Inducible production of c-fos antisense RNA inhibits 3T3 cell proliferation. Proc Natl Acad Sci U S A. 1986;83:4794-4798.
91. Halazonetis TD, Georgopoulos K, Greenberg ME, Leder P. c-jun dimerizes with itself and with c-fos, forming complexes of different DNA binding affinities. Cell. 1988;55:917-924.
92. Lamer AC, David M, Feldman GM, Igarashi K, Hackett RH, Webb DSA, Sweitzer SM, Petricoin EF, Finbloom DS. Tyrosine phosphorylation of DNA binding proteins by multiple cytokines. Science. 1993;261:1730-1733.
93. Silvennoinen O, Schindler C, Schlessinger J, Levy DE. Rasindependent growth factor signaling by transcription factor tyrosine phosphorylation. Science. 1993;261:1736-1739.
94. Wilentz JR, Sanborn TA, Haudenschild CC, Valeri CR, Ryan TJ, Faxon DP. Platelet accumulation in experimental angioplasty: time course and relation to vascular injury. Circulation. 1987;75: 636-642.
95. Moore S, Friedman RJ, Singal DP, Gauldie J, Blajchman MA, Roberts RS. Inhibition of injury induced thromboatherosclerotic lesions by anti-platelet serum in rabbits. Thromb Haemost. 1975; 35:70-81.
96. Topol EJ, Califf RM, Weisman HS, Ellis SG, Tcheng JE, Sigmon K, Anderson K, Lee KL, Willerson JT, for the EPIC Investigators. Reduction of clinical restenosis following coronary intervention with early administration of platelet IIb/IIIa integrin blocking antibody. Lancet. 1994;343:881-886.
97. Liu MW, Roubin GS, King SB III. Restenosis after coronary angioplasty: potential biologic determinants and role of intimal hyperplasia. Circulation. 1989;79:1374-1387.
98. Balduini CL, Sinigaglia F, Bertolino G, Bisio A, Noris P, Ascari E. Surface mechanisms of platelet adhesion and aggregation. Haematologica. 1987;72:261-268.
99. Kaplan AV, Leung LL-K, Leung W-H, Grant GW, McDougall IR, Fischell TA. Roles of thrombin and platelet membrane glycoprotein IIb/IIIa in platelet-subendothelial deposition after angioplasty in an ex vivo whole artery model. Circulation. 1991; 84:1279-1288.
100. Sarembock IJ, Gertz SD, Gimple LW, Owen RM, Powers ER, Roberts WC. Effectiveness of recombinant desulphatohirudin in reducing restenosis after balloon angioplasty of atherosclerotic femoral arteries in rabbits. Circulation. 1991;84:232-243.
101. Simari RD, Camrud AR, Jorgenson MA, Edwards WD, Schwartz RS. Ancrod and heparin reduce reactive neointimal hyperplasia in a porcine coronary injury model. Circulation. 1993;88(suppl I):I-657. Abstract.
102. Schwartz RS, Edwards WD, Camrud AR, Jorgenson MA, Holmes DRJ, Johnson RGJ. Tick anticoagulant peptide (TAP) inhibits neointimal thickening in a porcine coronary artery model. Circulation. 1993;88(suppl I):I-656. Abstract.
103. Shi Y, Fard A, Vermani P, Zalewski A. c-myc antisense oligomers reduce neointima formation in porcine coronary arteries. J Am Coll Cardiol. 1994;23:395A. Abstract.
104. Biro S, Fu YM, Yu ZX, Epstein SE. Inhibitory effects of antisense oligodeoxynucleotides targeting c-myc mRNA on smooth muscle cell proliferation and migration. Proc Natl Acad Sci U S A. 1993;90:654-658.
105. Morishita R, Gibbons GH, Ellison KE, Nakajima M, Zhang L, Kaneda Y, Ogihara T, Dzau J. Single intraluminal delivery of antisense cdc2 kinase and proliferating-cell nuclear antigen oligonucleotides results in chronic inhibition of neointimal hyperplasia. Proc Natl Acad Sci U S A. 1993;90:8474-8478.
106. Epstein SE, Speir E, Finkel T. Do antisense approaches to the problem of restenosis make sense? Circulation. 1993;88: 1351-1353.
107. Takenawa T, Fukami K. Phosphoinositide metabolism and oncogenes. Clin Chim Acta. 1989;185:309-316.
108. Ullrich A, Schlessinger J. Signal transduction by receptors with tyrosine kinase activity. Cell. 1990;61:203-212.
109. Moses HL, Yang EY, Pietenpol JA. TGF-beta stimulation and inhibition of cell proliferation: new mechanistic insights. Cell. 1990;63:245-247.
110. Edelman ER, Nugent MA, Smith LT, Karnovsky MJ. Basic fibroblast growth factor enhances the coupling of intimai hyperplasia and proliferation of vasa vasorum in injured rat arteries. J Clin Invest. 1992;89:465-473.
111. Nabel EG, Yang ZY, Plautz G, Forough R, Zhan X, Haudenschild CC, Maciag T, Nabel GJ. Recombinant fibroblast growth factor-1 promotes intimai hyperplasia and angiogenesis in arteries in vivo. Nature. 1993;362:844-846.
112. Friesel R, Komoriya A, Maciag T. Inhibition of endothelial cell proliferation by gamma-interferon. J Cell Biol. 1987;104:689-696.
113. Hansson GK, Holm J. Interferon-gamma inhibits arterial stenosis after injury. Circulation. 1991;84:1266-1272.
114. Heyns AP, Eldor A, Vlodavsky I, Kaiser N, Fridman R, Panet A. The antiproliferative effect of Interferon and the mitogenic activity of growth factors are independent cell cycle events: studies with vascular smooth muscle cells and endothelial cells. Exp Cell Res. 1985;161:297-306.
115. Fairbanks KP, Witte LD, Goodman DS. Relationship between mevalonate and mitogenesis in human fibroblasts stimulated with platelet-derived growth factor. J Biol Chem. 1984;259:1546-1551.
116. Schneider JE, Berk BC, Gravanis MB, Santoian EC, Cipolla GD, Tarazona N, Lassegue B, King SB. Probucol decreases neointimal formation in a swine model of coronary artery balloon injury: a possible role for antioxidants in restenosis. Circulation. 1993;88: 628-637.
117. Steele PM, Chesebro JH, Stanson AW, Holmes DR, Dewanjee MK, Badimon L, Fuster V. Balloon angioplasty: natural history of the pathophysiological response to injury in a pig model. Circ Res. 1985;57:105-112.
118. Schwartz RS, Holmes DR, Topol EJ. The restenosis paradigm revisited: an alternative proposal for cellular mechanisms. J Am Coll Cardiol. 1992;20:1284-1293.
119. Rab ST, King SB, Roubin GS, Carlin S, Hearn JA, Douglas JS Jr. Coronary aneurysms after stent placement: a suggestion of altered vessel wall healing in the presence of anti-inflammatory agents. J Am Coll Cardiol. 1991;18:1524-1528.
120. Hoyne J, Mahon DJ, Jain A, White CJ, Ramee SR, Wallis JB, Al-Zarka A, Tobis JM. Morphological effects of coronary balloon angioplasty in vivo assessed by intravascular ultrasound imaging. Circulation. 1992;85:1012-1025.
121. Simons M, Leclerc G, Safian RD, Isner JM, Weir L, Baim DS. Relation between activated smooth-muscle cells in coronaryartery lesions and restenosis after atherectomy. N Engl J Med. 1993;328:608-613.
122. Nabel EG, Plautz G, Boyce FM, Stanley JC, Nabel GJ. Recombinant gene expression in vivo within endothelial cells of the arterial wall. Science. 1989;244:1342-1344.